证券代码：603139 证券简称：康惠股份 公告编号：2025-080 陕西康惠制药股份有限公司 1、审议通过《关于变更公司经营范围并修订<公司章程>的议案》 公司在现有经营范围基础上，同时结合市场监督管理部门对经营范围规范表 述的要求，拟对公司经营范围进行变更并对《公司章程》中经营范围相关条款进 行修订。本次变更经营范围并修订《公司章程》，符合公司战略规划及经营发展 需要。 具体内容详见同日公司在上海证券交易所网站（http://www.sse.com.cn） 披露的 2025-081 号公告。 该议案在提交董事会审议前已经董事会战略委员会审议通过，尚需提交 第六届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 陕西康惠制药股份有限公司（以下简称"公司"）第六届董事会第五次会议 通知于 2025 年 12 月 5 日以电子邮件和专人送出方式送达全体董事，于 2025 年 12 月 10 日以现场与通讯相结合的方式召开。本次董事会会议应出席董事 9 人， 实际参加董事 9 人， ...

Group 1 - The core viewpoint of the article highlights that Kanghui Co., Ltd. (SH 603139) held its fifth meeting of the sixth board of directors on December 10, 2025, to discuss the proposal for the fourth extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Kanghui's revenue composition is as follows: pharmaceutical manufacturing accounts for 60.68%, pharmaceutical distribution for 36.79%, and other businesses for 2.53% [1] - As of the report, Kanghui's market capitalization stands at 2.2 billion yuan [1] Group 2 - The article mentions that the price of Feitian Moutai has dropped by 43% over the past two years, indicating a significant change in the market dynamics for this product [1] - The report raises concerns about the sustainability of profits for distributors, suggesting that the market may be facing challenges as the "tide recedes" [1]

Market Overview - The traditional Chinese medicine sector experienced a decline of 0.28% on December 8, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Xinguang Pharmaceutical (300519) with a closing price of 17.34, up 3.96% and a trading volume of 131,800 shares, totaling 229 million yuan [1] - Kanghui Co., Ltd. (603139) closed at 22.35, up 2.48% with a trading volume of 20,300 shares, totaling 45.04 million yuan [1] - Conversely, Weikang Pharmaceutical (300878) saw a significant decline of 8.00%, closing at 22.66 with a trading volume of 110,800 shares, totaling 251 million yuan [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 723 million yuan from institutional investors, while retail investors saw a net inflow of 469 million yuan [2] - The capital flow for specific stocks showed: - Yunnan Baiyao (000538) had a net inflow of 26.56 million yuan from institutional investors, while retail investors had a net outflow of 6,450 yuan [3] - Kang Enbei (600572) reported a net inflow of 21.85 million yuan from institutional investors, with a net outflow of 1.92 million yuan from retail investors [3]

证券日报网讯12月1日，康惠股份（603139）在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东人数为9458户。 ...

证券代码：603139 证券简称：康惠股份 公告编号：2025-079 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,005.68 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 12.84 | 一、担保情况概述 （一） 担保的基本情况 2025 年 12 月 1 日，四川春盛药业集团股份有限公司（以下简称"春盛药业"） 到期归还了成都农村商业银行股份有限公司都江堰柳河支行（以下简称"成都农 商行"）贷款 1,000 万元人民币，同日，春盛药业与成都农商行签署《流动资金 借款合同》，成都农商行拟向春盛药业提供借款 980 万元人民币，借款期限为 12 个月，借款用途为：采购中药材。陕西康惠制药股份有限公司（以下简称"公 司"）作为担保方与成都农商行签署《保证合同》，为该笔借款提供连带责任保 ...

截至发稿，康惠股份市值为22亿元。 （记者 王晓波） 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ 每经AI快讯，康惠股份（SH 603139，收盘价：22元）12月1日晚间发布公告称，截至本公告披露日， 公司为控股子公司提供担保余额约为1.07亿元，控股子公司为其全资子公司提供的担保余额为280万 元，公司及控股子公司提供担保总额占公司最近一期经审计归母净资产的12.84%。 2025年1至6月份，康惠股份的营业收入构成为：医药制造占比60.68%，医药流通占比36.79%，其他业 务占比2.53%。 ...

重要内容提示： 证券代码：603139 证券简称：康惠股份 公告编号：2025-078 陕西康惠制药股份有限公司 关于业绩补偿事项申请仲裁暨累计诉讼的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 案件所处的仲裁阶段：咸阳仲裁委员会已受理 ● 全资子公司所处的当事人地位：仲裁申请人 ● 涉案的金额：1,414.34 万元（菩丰堂原股东张雨需支付 2023 年度和 2024 年度业绩补偿款 721.31 万元、黎勇需支付 2023 年度和 2024 年度业绩补偿款 325.30 万元、黎英需支付 2023 年度和 2024 年度业绩补偿款 162.65 万元、沈传 玖需支付 2023 年度和 2024 年度业绩补偿款 162.65 万元、沈家胜需支付 2023 年度和 2024 年度业绩补偿款 42.43 万元）及本案仲裁费用。 ● 是否会对上市公司损益产生影响：鉴于案件尚未开庭审理，仲裁结果存 在不确定性，暂无法判断对公司本期或期后利润影响。 一、业绩补偿事项的基本情况 2021 年 5 月，公司全资子公司陕西康惠 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

重要内容提示： 一、关于新增 2025 年度日常关联交易额度的情况 （一）履行的审议程序 1、独立董事专门会议审议情况 公司于 2025 年 11 月 15 日召开 2025 年第二次独立董事专门会议，审议通过 《关于补充预计 2025 年度日常关联交易事项的议案》。全体独立董事认为：公 司及控股子公司与关联企业之间的日常关联交易，能充分利用关联方拥有的资源 和优势为公司的生产经营服务，实现资源合理配置，定价模式符合诚实、信用、 公正的原则，不存在损害公司和其他股东利益的情形，上述交易不影响公司独立 性，公司的主要业务不会因此类交易而对关联人形成依赖。全体独立董事同意《关 于补充预计 2025 年度日常关联交易事项的议案》，并同意将《关于补充预计 2025 年度日常关联交易事项的议案》提交公司第六届董事会第四次会议审议。 2、审计委员会审议情况 证券代码：603139 证券简称：康惠股份 公告编号：2025-077 陕西康惠制药股份有限公司 关于新增 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承 ...

Meeting Overview - The shareholder meeting was held on November 14, 2025, at the company's headquarters in Beijing [1] - The meeting was convened by the board of directors and was conducted both in-person and via online voting, presided over by Chairman Li Hongming [1] Attendance - All 9 current directors attended the meeting, along with the board secretary and senior management [2] - A witnessing lawyer from a reputable law firm was also present [2] Agenda and Resolutions - A key agenda item was the proposal for the provision of bad debt reserves for receivables, which was approved [3] - The voting process was non-cumulative, and the proposal required separate voting for minority investors [3] Legal Verification - The meeting was witnessed by lawyers from a well-known law firm, confirming that the procedures followed were in compliance with relevant laws and regulations [4][5] - The lawyers concluded that the meeting's convening, attendance, and voting processes were all legally valid [5]